CLB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Core Laboratories's average Accounts Receivable for the three months ended in Mar. 2025 was $114.4 Mil. Core Laboratories's Revenue for the three months ended in Mar. 2025 was $123.6 Mil. Hence, Core Laboratories's Days Sales Outstanding for the three months ended in Mar. 2025 was 84.47.
The historical rank and industry rank for Core Laboratories's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Core Laboratories's highest Days Sales Outstanding was 81.36. The lowest was 68.29. And the median was 76.48.
Core Laboratories's Days Sales Outstanding increased from Mar. 2024 (78.99) to Mar. 2025 (84.47).
The historical data trend for Core Laboratories's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Core Laboratories Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial |
![]() |
![]() |
80.44 | 69.86 | 75.92 | 77.42 | 77.03 |
Core Laboratories Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Days Sales Outstanding | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
78.99 | 80.62 | 79.18 | 80.97 | 84.47 |
For the Oil & Gas Equipment & Services subindustry, Core Laboratories's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Oil & Gas industry and Energy sector, Core Laboratories's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Core Laboratories's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Core Laboratories's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as
Days Sales Outstanding (A: Dec. 2024 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2023 ) | + | Accounts Receivable (A: Dec. 2024 )) | / | count ) | / | Revenue (A: Dec. 2024 ) | * | Days in Period |
= | ( (109.352 | + | 111.761) | / | 2 ) | / | 523.848 | * | 365 |
= | 110.5565 | / | 523.848 | * | 365 | ||||
= | 77.03 |
Core Laboratories's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:
Days Sales Outstanding (Q: Mar. 2025 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2024 ) | + | Accounts Receivable (A: Mar. 2025 )) | / | count ) | / | Revenue (A: Mar. 2025 ) | * | Days in Period |
= | ( (111.761 | + | 117.031) | / | 2 ) | / | 123.585 | * | 365 / 4 |
= | 114.396 | / | 123.585 | * | 365 / 4 | ||||
= | 84.47 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Core Laboratories (NYSE:CLB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Core Laboratories's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Katherine Murray | director | 6316 WINDFERN ROAD, HOUSTON TX 77040 |
Mark Damian Tattoli | officer: SVP, Gen Counsel & Secretary | C/O CORE LABORATORIES LP, 6316 WINDFERN ROAD, HOUSTON TX 77040 |
Kwaku Temeng | director | C/O CORE LABORATORIES LP, 2216 SHERIDAN STREET, HOUSTON TX 77002 |
Gwendolyn Schreffler | officer: SVP | C/O CORE LABORATORIES LP, 6316 WINDFERN ROAD, HOUSTON TX 77040 |
Harvey Robert Klingensmith | director | P.O. BOX 131144, HOUSTON TX 77219-1114 |
Van Dijken Eeuwijk Monique | director | P.O. BOX 129, BILTHOVEN P7 3720 AC |
Jan Willem Sodderland | director | DUINDISTEL 89, NOORDWIJK P7 2202 DE |
Goldman Sachs Group Inc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Goldman Sachs & Co. Llc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Lawrence Bruno | officer: President | 6316 WINDFERN ROAD, HOUSTON TX 77040 |
Mark F Elvig | officer: VP, Counsel & Secretary | 6316 WINDFERN, HOUSTON TX 77040 |
Gregory Barry Barnett | director | 853 MILWAUKEE STREET, DENVER CO 80206 |
Kevin Daniels | officer: CAO & Treasurer | 6316 WINDFERN ROAD, HOUSTON TX 77040 |
Michael Straughen | director | 68 RUBISLAW DEN NORTH, ABERDEEN X0 AB15 4AN |
Martha Z. Carnes | director | 6316 WINDFERN ROAD, HOUSTON TX 77040 |
From GuruFocus
By GuruFocus News • 10-25-2024
By PRNewswire • 03-24-2025
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 02-15-2024
By GuruFocus News • 01-29-2025
By PRNewswire • 07-24-2024
By GuruFocus News • 02-14-2025
By GuruFocus News • 10-24-2024
By PRNewswire • 01-03-2025
By GuruFocus News • 11-21-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.